insights_auto
Dlaczego cena akcji EVO spadła 4,82%?
Dowiedz się więcejchevron_right
EVO:NASDAQ
Evotec SE
1,58 USD
arrow_downward
-4,82%(-0,080) 1D
13 lis, 16:00:01 GMT-5 · USD
search
Wszystkie symbole
| Symbol | Cena | Zmiana | Zmiana % |
|---|
insights_autoGeneruję najważniejsze statystyki dotyczące: EVO…
Otwarcie
1,62 USD
Maks.
1,63 USD
Min.
1,57 USD
Kapitalizacja
584,84 mln
Śr. wol.
98,48 tys.
Wolumen
46,51 tys.
Najwyższa z 52 tyg.
3,87 USD
Minimum z 52 tyg.
1,33 USD
Zysk na akcję
-0,56 USD
Beta
2,02
Akcje w obiegu
355,82 mln
Liczba pracowników
4 tys.
Otwarcie
1,62 USD
Maks.
1,63 USD
Min.
1,57 USD
Kapitalizacja
584,84 mln
Śr. wol.
98,48 tys.
Wolumen
46,51 tys.
Najwyższa z 52 tyg.
3,87 USD
Minimum z 52 tyg.
1,33 USD
Zysk na akcję
-0,56 USD
Beta
2,02
Akcje w obiegu
355,82 mln
Liczba pracowników
4 tys.
Wiadomości
Ze źródeł internetowych i od partnerskich agencji informacyjnych
TradingKey
·
7 godzin temu
S&P 500 Forecast: Index Poised to Retest Record High in November After 500-Point Pullback, Biggest Daily Gain in Nearly Seven Months
Foreign Policy Journal
·
6 godzin temu
Dow Jones Industrial Average (DJIA) Stays Green While Nasdaq Tumbles Nearly 1% In Sharp Rotation Trade
24/7 Wall St.
·
10 godzin temu
He Thinks His $200,000 S&P 500 401(k) Spreads His AI Risk. Two Alphabet Share Classes Put $10,380 in One Company. A 20% Drop Could Cost Him $2,076
Traders Union
·
14 godzin temu
Michael Kantro: Institutional investors focus on stock picking as S&P 500 targets have lost relevance
Profil
Evotec SE is a publicly listed drug discovery and development company headquartered in Hamburg, Germany. The company operates globally, largely through external alliances with pharmaceutical and biotechnology companies, academic institutions, patient advocacy groups, and venture capitalists. As of 31 December 2021 Evotec had a market capitalization of €7.5 billion and a pipeline of more than 130 partnered programs in discovery, pre-clinical development and clinical development.
The company's 4,200+ employees work across a number of therapeutic areas including CNS/neurology, metabolic diseases, Cancer, and inflammatory and infectious diseases. It has long-term discovery alliances with Bristol Myers Squibb, Bayer, Sanofi, Boehringer Ingelheim, the CHDI Foundation, Lilly, Takeda, Sernova, and more.
On 28 October 2009 the company was listed on the TecDAX index, which tracks the performance of the 30 largest German companies from the technology sector. On 24 September 2018 Evotec joined the MDAX index, following a rule change that enabled dual listing. The MDAX tracks 60 Prime Standard shares from sectors excluding technology. Wikipedia
Evotec SE – informacje
Prezes-
Pracownicy4,38 tys.
Data założenia1993
Siedziba główna-
SektorHealth Care
Branża-
Witrynaevotec.com